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Abstract
Purpose To understand how improvements in the symptoms
of overactive bladder (OAB) seen with the b3-adrenoceptor
agonist mirabegron 50 mg, correlate with patient experience
as measured by validated and standard patient-reported
outcomes (PROs), and to identify whether there is overall
directional consistency in the responsiveness of PROs to
treatment effect.
Methods In a post hoc analysis of pooled data from three
randomized, double-blind, placebo-controlled, 12-week
Phase III trials of mirabegron 50 mg once daily, responder
rates for incontinence frequency (C50 % reduction in
incontinence episodes/24 h from baseline to final visit),
micturition frequency (B8 micturitions/24 h at final visit),
and PROs [minimally important differences in patient
perception of bladder condition (PPBC) and subsets of the
overactive bladder questionnaire (OAB-q) measuring total
health-related quality of life (HRQoL), and symptom
bother] were evaluated individually and in combination.
Results Mirabegron 50 mg demonstrated greater
improvement from baseline to final visit than placebo for
each of the responder analyses, whether for individual
objective and subjective outcomes or combinations thereof.
These improvements versus placebo were statistically sig-
nificant for all double and triple responder analyses and for
all single responder analyses except PPBC. PRO mea-
surements showed directional consistency and significant
correlations, and there were also significant correlations
between objective and subjective measures of efficacy.
Conclusions The improvements in objective measures
seen with mirabegron 50 mg translate into a meaningful
clinical benefit as evident by the directional consistency
seen in HRQoL measures of benefit.
Keywords Mirabegron  Overactive bladder  Patient-
reported outcomes  Quality of life  Correlation
Introduction
Overactive bladder (OAB) is defined by symptoms of
urinary urgency, usually accompanied by frequency and
nocturia, with or without urgency incontinence, in the
absence of urinary tract infection (UTI) or other obvious
pathology [1]. This condition is estimated to affect
12–17 % of adults in Europe and the USA [2–5]. OAB is
associated with anxiety and depression [6–8], impairment
of work productivity [9], and daily activities [10–12]. It is
therefore associated with detrimental effects on health-
related quality of life (HRQoL) [13]. Indeed, the severity of
urgency urinary incontinence has been shown to be a
predictor for HRQoL [14].
Clinical trials of treatments for the symptoms of OAB
have traditionally relied on objective outcome measures to
evaluate treatment efficacy, of which the most commonly
used are those recorded in a patient bladder diary, namely
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micturition frequency, number of incontinence and urgency
episodes in a 24 h period, number of nocturia episodes per
24 h, and volume voided per micturition [15, 16]. However,
these endpoints say little about the impact that symptoms
have on the patient’s quality of life (QoL) [17]. Indeed, it
has been reported that improvements in objective outcomes
do not necessarily correlate with improvements in subjective
outcomes, that is, they do not necessarily translate into
improvements in HRQoL [15, 16]. Consequently, there is a
growing appreciation of the need to understand health out-
comes from the patient’s point of view [18–21], particularly
for the treatment of chronic debilitating conditions such as
OAB, for which treatment is often aimed at symptom
management rather than cure. The International Continence
Society recommends that QoL measures be evaluated in the
assessment of therapeutic interventions for the management
of the symptoms of OAB [22].
A patient’s likelihood of persisting with a treatment for
OAB is related to their satisfaction with that treatment [23].
Improvements in objective measures, such as micturition
frequency, without a concomitant improvement in patient-
reported measures of HRQoL, may not be sufficient to
persuade the patient to persist with treatment. Indeed,
improvements in objective outcomes achieved with com-
mon OAB drugs have typically not translated into long-
term persistence; persistence rates ranging from 8 to 29 %
have been reported in studies with at least 1 year of follow-
up [24–27]. On the other hand, statistically significant
improvements from baseline in the patient perception of
bladder condition (PPBC) score have been seen in an open-
label study of darifenacin along with treatment satisfaction
for 85 % of patients [28].
Mirabegron is the first in a new class of agents—the
b3-adrenoceptor agonists—to be approved for the treatment of
OAB. In addition to objective bladder diary outcomemeasures,
a range of PROs were evaluated in three randomized, double-
blind, placebo-controlled, 12-week Phase III clinical trials
(Studies 046 (NCT00689104) [29], 047 (NCT00662909) [30],
and 074 (NCT00912964) [31]). Co-primary (objective) out-
come measures in all three studies were change from baseline
to final visit inmean number ofmicturitions per 24 h andmean
number of incontinence episodes per 24 h. Patient-reported
outcomes (PROs) included the overactive bladder question-
naire (OAB-q), the PPBC, and the treatment satisfaction visual
analog scale (TS-VAS). In all three Phase III studies, and in a
pre-specified, pooled analysis of the three studies [32], mira-
begron 50 mg once daily resulted in statistically significant
improvements from baseline to final visit versus placebo on
both co-primary outcomes. It also resulted in a statistically
significant improvement from baseline to final visit compared
with placebo on PPBC as well as on the symptom bother scale
and total HRQoL of the OAB-q in all three studies and the
OAB-q subscales of coping and concern in Studies 046 and
047. Statistically significant improvement relative to placebo in
theOAB-q subscale of sleepwas also reportedwithmirabegron
50 mg in Study 047. In the pooled analysis, the only PRO
reported was the TS-VAS; this too showed a statistically sig-
nificant improvement from baseline to final visit for mirabeg-
ron 50 mg versus placebo. Analysis of the pooled data has also
shown greater improvement in the EQ-5D utility score with
mirabegron 50 mg compared with placebo and tolterodine
[33].
This paper presents the results of post hoc analysis con-
ducted on the large pooled mirabegron 50 mg and placebo
data sets described above to determine correlations between
various objective and subjective outcomemeasures utilized in
the three Phase III trials. (The 25 mg dose was not evaluated
in this post hoc analysis as it was used in Study 074 only and
hence was not part of the pooled analysis.) Data showing the
effects of mirabegron 50 mg on measures of HRQoL are also
presented. In a novel approach to understanding these data,
responder analyseswere performed to assess the proportion of
patients who were simultaneously responders for inconti-
nence episodes and micturitions along with one or two dif-
ferent PROs at final visit. The aims were twofold: firstly, to
understand how improvements in objective measures with
mirabegron 50 mg correlate with the patient’s experience as
measured by validated, standard PRO instruments and sec-
ondly, to understand how improvements in different PRO
outcomes correlate with one another. This is of interest
because PROs assess different components of the response of
patients, resulting in heterogeneity in responsiveness to
treatment effect.
Methods
Study design
An overview of the design of Studies 046, 047, and 074 is
provided in Table 1. Importantly, all three studies were of
identical design, the only difference being the inclusion of
tolterodine as an active control in Study 046 (but not
Studies 047 or 074) and the use of mirabegon 25 mg, but
not mirabegron 100 mg in Study 074.
Efficacy assessments
Objective measures
Co-primary efficacy outcome measures in all three studies
were change from baseline to final visit in mean number of
incontinence episodes per 24 h and change from baseline to
final visit in mean number of micturitions per 24 h. A
responder for incontinence episodes was defined as a patient
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who had incontinence at baseline and a C50 % decrease
from baseline to final visit in mean number of incontinence
episodes per 24 h. A responder for micturition frequency
was defined as a patient with B8 micturitions per 24 h at
final visit. (Note that the results of a responder analysis of
incontinence frequency have been reported for Studies 046
and 074 [29, 31] as have the results of responder analyses of
both incontinence and micturition frequency in a pooled
analysis of all three studies [32].)
Subjective measures
Patient-reported outcomes evaluated in all three studies
include change from baseline to final visit in PPBC, OAB-q
symptom bother scale, OAB-q total HRQoL, and the
OAB-q subscales of coping, concern, sleep, and social
interaction. The PPBC was developed as a global assessment
of bladder condition that asks patients to rate their subjective
impression of their current bladder condition on a 6-point
Likert scale, ranging from 1 (‘‘my bladder condition does not
cause me any problems at all’’) to 6 (‘‘my bladder condition
causes me many severe problems’’). The OAB-q symptom
bother scale measures level of bother associated with OAB
symptoms and is assessed using the eight items that comprise
the symptom bother scale of the 33-item OAB-q. Total
HRQoL, measured using the remaining 25 items of the OAB-
q, is comprised of four subscales—coping, concern, sleep,
and social interaction. Both the PPBC and the OAB-q have
been validated in clinical and community settings and have
demonstrated reliable internal consistency, test–retest reli-
ability, construct validity, and responsiveness among patients
with a range of OAB symptoms [34–38].
Patient perception of bladder condition was assessed at
baseline and week 12/final visit. Higher scores on the PPBC
indicate a poorer perception of bladder condition and negative
values for change frombaseline scores indicate improvement.
OAB-q was assessed at baseline and weeks 4, 8, and 12/final
visit, and scores transformed onto a 0–100 scale. OAB-q total
HRQoL and subscale scores are directly related to patient
wellbeing with higher scores indicating better QoL and a
positive change in scores indicating improvement. The score
on the OAB-q symptom bother scale is directly related to the
degree of patient discomfort (bother) with the symptoms of
OAB. Hence, lower scores on this scale indicate a better QoL,
and a negative change in the symptom bother scale indicates
improvement.
For the responder analysis of PROs, a responder was
defined as a patient who achieved a change from baseline
to final visit that exceeded the minimally important dif-
ference (MID), which is defined as ‘‘the smallest difference
in score in the domain of interest that patients perceive as
beneficial and which would mandate, in the absence of
troublesome side effects and excessive costs, a change in
patient management’’ [39]. The MID has been defined to be
10 points for OAB-q (symptom bother, total HRQoL, and
subscales) based on anchor and distribution methods [34,
40, 41] and 1 point for PPBC [38].
Statistical analyses
The full analysis set (FAS) in all three studies comprised
all randomized patients who received at least one dose of
study drug and had at least one micturition measurement in
a 3-day micturition diary at baseline and at least one post-
baseline diary. The FAS-incontinence (FAS-I) population
comprised FAS patients who also recorded at least one
incontinence episode in the 3-day baseline diary. Data for
the placebo and mirabegron 50 mg arms of all three studies
Table 1 Overview of design of Studies 046, 047, and 074
Study Location Study design Duration of treatment Inclusion criteria Treatment groups
046 189 sites in
Australia
and Europe
046: Phase III, randomized,
double-blind, placebo- and
active-controlled study to
evaluate the efficacy and safety
of mirabegron
2-week single-blind,
placebo run-in period
followed by 12-week
double-blind treatment
period
Female and male adults aged
C18 years who had symptoms of
OAB (urinary frequency and
urgency with or without
incontinence) for C3 months and
C8 micturitions per 24 h during
3-day micturition diary period
collected during run-in period and
C3 urgency episodes (PPIUS scale
grade 3 or 4), with or without
incontinence during 3-day
micturition diary period collected
during run-in period
Placebo
Mirabegron 50 mg od
Mirabegron 100 mg od
Tolterodine ER 4 mg od
047 132 sites in
Canada and
USA
047 and 074: Phase III,
randomized, double-blind,
placebo-controlled studies to
evaluate the efficacy and safety
of mirabegron
Placebo
Mirabegron 50 mg od
Mirabegron 100 mg od
074 151 sites in
Canada,
USA, and
Europe
Placebo
Mirabegron 25 mg od
Mirabegron 50 mg od
OAB overactive bladder, od once daily, PPIUS Patient Perception of Intensity of Urgency Scale
 All three studies
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were pooled and change from baseline data analyzed using
analysis of covariance (ANCOVA) with treatment group, sex,
and study as fixed factors and baseline as a covariate. Pooling
of the data was facilitated by the fact that all three studies were
identical in design, with the same inclusion and exclusion
criteria andoutcomemeasurements (Table 1).Responder rates
for PROs, individually and in combination with responder
rates for incontinence frequency and micturition frequency,
were determined: the double responder analysis involved
evaluation of the proportions of patients who were simulta-
neously responders for either incontinence or micturitions as
well as PPBC, OAB-q symptom bother scale, or OAB-q total
HRQoL; the triple responder analysis involved evaluation of
the proportions of patients who were simultaneously
responders for either incontinence or micturitions as well as
PPBC andOAB-q symptombother scale or PPBC andOAB-q
total HRQoL. Two-sided 95 % confidence intervals (CIs) for
the differences in the proportions of responders between mir-
abegron 50 mg and placebo are based on normal approxima-
tion. Odds ratios, corresponding two-sided 95 % CIs, and
P values were derived from a logistic regression model
including treatment group, sex, study, and baseline value(s).
Spearman rank partial correlation coefficients, adjusted
for baseline, between the objective endpoints (change from
baseline to final visit in mean number of incontinence
episodes per 24 h and mean number of micturitions per
24 h) and each of the subjective outcomes (OAB-q
symptom bother scale, OAB-q total HRQoL, and PPBC)
were derived. Additionally, Spearman rank partial corre-
lation coefficients, adjusted for baseline, between change
from baseline to final visit in PPBC and change from
baseline to final visit in both the OAB-q symptom bother
scale and total HRQoL were derived.
Results
Study population
The pooled placebo and mirabegron 50 mg groups consisted
of 1,328 and 1,324 patients in the FAS, respectively, and 878
and 862 in the FAS-I, respectively. Patient demographics and
baseline characteristicswere similar in the pooled placebo and
pooled mirabegron 50 mg treatment groups (Table 2).
Efficacy
PRO outcomes
Mirabegron 50 mg resulted in a statistically significant
improvement from baseline to final visit relative to placebo
in the OAB-q symptom bother scale and PPBC (P\ 0.05,
Fig. 1). It also resulted in statistically significant
improvements from baseline to final visit relative to pla-
cebo in OAB-q total HRQoL and the OAB-q subscales of
coping, concern, and sleeping, but not social interaction
(P\ 0.05, Fig. 2).
Responder analyses
The percentage of subjects in the mirabegron 50 mg and
placebo groups who were responders (i.e., achieved the
MID) at final visit was: 66.0 and 57.8 %, respectively, for
the OAB-q symptom bother scale, 56.8 and 48.9 % for
OAB-q total HRQoL, and 55.9 and 53.1 % for PPBC.
Thus, responder rates for the OAB-q symptom bother scale,
OAB-q total HRQoL, and PPBC were numerically larger
with mirabegron 50 mg than placebo; the odds ratios for
Table 2 Patient demographics and baseline characteristics by pooled treatment group (FAS)
Placebo (n = 1,328) Mirabegron 50 mg (n = 1,324)
Females [n (%)] 966 (72.7) 942 (71.1)
Age (years), mean (SD) 59.2 (13.2) 59.7 (12.6)
Race [n (%)]
White 1,227 (92.4) 1,235 (93.3)
Black or African-American 80 (6.0) 61 (4.6)
Asian 13 (1.0) 17 (1.3)
Other 8 (0.6) 11 (0.8)
Type of OAB [n (%)]
Urgency incontinence only 442 (33.3) 491 (37.1)
Mixed stress/urgency incontinence 415 (31.3) 412 (31.1)
Frequency/urgency without incontinence 471 (35.5) 421 (31.8)
Duration of OAB (months), mean (SD) 86.3 (99.1) 85.2 (93.1)
Number of incontinence episodes per 24 h, mean (SD) 1.8 (2.5) 1.8 (2.5)
Number of micturitions per 24 h, mean (SD) 11.6 (3.1) 11.7 (3.2)
FAS full analysis set, OAB overactive bladder, SD standard deviation
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mirabegron 50 mg versus placebo on responder rates were
all greater than one (Table 3). The difference in responder
rates between mirabegron 50 mg and placebo was statis-
tically significant for the OAB-q symptom bother scale and
OAB-q total HRQoL (P\ 0.001), and it approached, but
did not reach, statistical significance for PPBC. (Responder
rates for incontinence and micturition frequency were also
statistically significantly larger with mirabegron 50 mg
than placebo; these results have been reported previously
[32] and are shown in Table 3 for completeness.)
When responder rates for incontinence episodes were
analyzed in combination with responder rates for PPBC,
OAB-q symptom bother scale, or OAB-q total HRQoL to
identify patients who were simultaneously responders on
two (double responder analysis) or three (triple responder
analysis) outcomes, mirabegron 50 mg demonstrated sta-
tistically significantly greater responder rates compared
with placebo in all analyses (P\ 0.001, Table 3). Like-
wise, when responder rates for micturition frequency were
analyzed in combination with responder rates for one or
two PRO outcomes, mirabegron 50 mg demonstrated sta-
tistically significantly greater responder rates compared
with placebo in all analyses (P\ 0.001).
Correlation analyses
For PPBC and the OAB-q symptom bother scale, a negative
change from the baseline value indicates patient improve-
ment; thus, a positive Spearman rank correlation coefficient
as shown in Table 4 indicates correlation between the
improvement from baseline to final visit for PPBC and that
for OAB-q symptom bother scale. Meanwhile, for OAB-q
total HRQoL, a positive change from baseline value indicates
patient improvement; thus, a negative Spearman rank cor-
relation coefficient as shown in Table 4 indicates correlation
between the improvement from baseline to final visit for
PPBC and that for OAB-q total HRQoL. Both correlations
were statistically significant (P\ 0.0001). There were also
significant correlations between change from baseline to final
visit in both objective measures—mean number of inconti-
nence episodes per 24 h and mean number of micturitions
per 24 h—and change from baseline to final visit in each of
the subjective measures—OAB-q symptom bother scale,
OAB-q total HRQoL, and PPBC (P\ 0.0001, Table 4).
Discussion
These data extend what has been previously published: in a
pooled analysis of three 12-week Phase III studies, mira-
begron 50 mg not only resulted in statistically significant
improvements versus placebo in change from baseline to
final visit in the objective outcomes of mean number of
incontinence episodes and mean number of micturitions per
24 h, but also resulted in statistically significant improve-
ments versus placebo in change from baseline to final visit in
PPBC, the OAB-q symptom bother scale, OAB-q total
HRQoL, and OAB-q subscales of coping, concern, and
sleeping, but not social interaction. The social interaction
subscale has traditionally been the least responsive of the
OAB-q subscales to improvement in patients’ wellbeing, so
these results are not surprising [35, 36].
The improvements produced by mirabegron 50 mg on
PROs were also manifest in the proportion of subjects in
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whom the change from baseline exceeded the MID defined
for both the OAB-q (10 points) and PPBC (1 point)
instruments. Indeed, two-thirds of subjects who received
mirabegron 50 mg experienced a change in the OAB-q
symptom bother scale that exceeded the MID for that scale
(10 points). The MID values for OAB-q have been related
to changes in degrees of disease symptomatology that are
directly relevant to the patient’s experience of the disease,
such as resolution of incontinence. Hence, the results
demonstrate the meaningfulness of the observed thera-
peutic benefit experienced by the patient.
There was a significant correlation between change from
baseline in PPBC and that in the OAB-q symptom bother
scale and OAB-q total HRQoL. Moreover, these correla-
tions were large (0.60 and -0.62) [42] and similar to those
between PPBC, OAB-q symptom bother scale, and OAB-q
HRQoL reported by Coyne and co-workers [43] in a sim-
ilar post hoc analysis of data from a 12-week open-label
trial of tolterodine extended release. These results indicate
directional consistency in the response of these PROs to
mirabegron 50 mg.
Incontinence is a major symptom of OAB, occurring in
about one-third of patients, and is associated with signif-
icant morbidity, reduction in QoL, and serious limitations
to activities of daily living [44]. QoL scores in OAB
patients with incontinence have been shown to be con-
sistently lower than in OAB patients without incontinence
[44]. A statistically significant difference between mira-
begron 50 mg and placebo in the percentage of patients
who achieved a 50 % or greater reduction in incontinence
frequency at final visit has been seen previously [32]. In
the post hoc analyses described here, the unique approach
was taken to identify the proportion of patients who
simultaneously achieved a 50 % or greater reduction in
incontinence frequency at final visit and the MID in one
or two PROs. In all the analyses conducted, mirabegron
50 mg resulted in statistically significantly higher com-
posite responder rates than placebo. Moreover, improve-
ments in both incontinence and micturition frequency
were statistically significantly correlated with improve-
ments in each of PPBC, the OAB-q symptom bother scale,
and OAB-q total HRQoL. These correlation coefficients
were mostly of moderate magnitude (0.30–0.49) [42] and,
regardless of which PRO was examined, were similar for
incontinence and micturition frequency. A number of
studies have demonstrated the favorable effects of several
antimuscarinics on a number of different QoL measures
[45–49] and a small to moderate, but statistically signifi-
cant correlation between improvement in number of
urgency urinary incontinence episodes and PPBC has been
0
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Fig. 2 Adjusted mean change
(SE) from baseline to final visit
in OAB-q total HRQoL and its
subscales of coping, concern,
sleeping, and social interaction
with mirabegron 50 mg and
placebo (FAS; pooled data)
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Table 4 Spearman rank order correlation coefficients between objective and subjective outcome measures; pooled mirabegron 50 mg and
placebo data
Spearman rank
correlation
coefficient
P value
Correlation between change from baseline to final visit in
PPBC (FAS) and
OAB-q symptom bother score 0.62 \0.0001
OAB-q total HRQoL -0.60 \0.0001
Mean number of incontinence episodes per 24 h (FAS-I) and
OAB-q symptom bother score 0.40 \0.0001
OAB-q total HRQoL -0.33 \0.0001
PPBC 0.22 \0.0001
Mean number of micturitions per 24 h (FAS) and
OAB-q symptom bother score 0.42 \0.0001
OAB-q total HRQoL -0.37 \0.0001
PPBC 0.31 \0.0001
FAS full analysis set, FAS-I FAS-incontinence, HRQoL health-related quality of life, OAB-q overactive bladder questionnaire, PPBC patient
perception of bladder condition
Table 3 Single, double, and triple responder analyses for the pooled mirabegron 50 mg group versus placebo
Respondersa for: Difference versus
placebo % (95 % CIs)b
Odds ratio (95 % CIs)c P valuec
Single responder criterion
Incontinence (FAS-I) 9.9 (5.5, 14.4) 1.54 (1.26, 1.89) \0.001
Micturitions (FAS) 7.0 (3.6, 10.4) 1.57 (1.30, 1.89) \0.001
PPBC (FAS) 2.8 (-1.2, 6.7) 1.18 (0.99, 1.39) 0.059
OAB-q symptom bother score (FAS) 8.3 (4.5, 12.1) 1.43 (1.21, 1.70) \0.001
OAB-q total HRQoL (FAS) 7.9 (4.0, 11.8) 1.46 (1.23, 1.74) \0.001
Double responder criteria
Incontinence and PPBC (FAS-I) 6.8 (1.9, 11.6) 1.37 (1.11, 1.68) 0.003
Incontinence and OAB-q symptom bother score (FAS-I) 15.2 (10.4, 20.0) 1.87 (1.53, 2.29) \0.001
Incontinence and OAB-q total HRQoL (FAS-I) 10.9 (6.1, 15.7) 1.60 (1.30, 1.97) \0.001
Micturitions and PPBC (FAS) 3.9 (0.8, 7.1) 1.42 (1.14, 1.77) 0.001
Micturitions and OAB-q symptom bother score (FAS) 6.7 (3.4, 10.0) 1.59 (1.30, 1.95) \0.001
Micturitions and OAB-q total HRQoL (FAS) 6.0 (3.0, 9.1) 1.63 (1.31, 2.02) \0.001
Triple responder criteria
Incontinence and PPBC and OAB-q symptom bother score
(FAS-I)
9.1 (4.2, 13.9) 1.55 (1.24, 1.93) \0.001
Incontinence and PPBC and OAB-q total HRQoL (FAS-I) 8.4 (3.6, 13.2) 1.51 (1.20, 1.90) \0.001
Micturitions and PPBC and OAB-q symptom bother score (FAS) 3.5 (0.4, 6.6) 1.42 (1.12, 1.79) 0.003
Micturitions and PPBC and OAB-q total HRQoL (FAS) 3.6 (0.7, 6.5) 1.47 (1.15, 1.88) 0.002
CI confidence interval, FAS full analysis set, FAS-I FAS-incontinence, HRQoL health-related quality of life, PPBC patient perception of bladder
condition
a Responder definitions: incontinence, C50 % reduction in incontinence episodes per 24 h from baseline to final visit; micturitions, B8
micturitions per 24 h at final visit; PPBC, OAB-q symptom bother score, and OAB-q total HRQoL, change from baseline to final
visit C minimally important difference (10 points for OAB-q total HRQoL and OAB-q symptom bother score and 1 point for PPBC
b 95 % two-sided CIs for the differences between mirabegron 50 mg and placebo in proportions of responders are based on normal
approximation
c Odds ratios, corresponding two-sided 95 % CIs, and P values are derived from a logistic regression model including treatment group, sex,
study, and baseline value(s)
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reported in a 12-week trial of tolterodine extended release
[50]. However, no studies of antimuscarinics have evalu-
ated composite responder rates as done here.
In conclusion, it appears that the improvements inobjective
outcome measures seen with mirabegron 50 mg are mirrored
by statistically significant improvements in the clinically rel-
evant PROmeasurements ofOAB-q totalHRQoL, PPBC, and
OAB-q symptom bother scale. Moreover, there is directional
consistency in the effect of mirabegron 50 mg across the
disparate domains measured by various objective outcomes
and PROs. Thus, improvement in objective outcomes trans-
lates into a meaningful clinical benefit; the OAB-q and PPBC
appear to provide a clinically relevant perspective on OAB
management, and the objective outcomes of incontinence and
micturition frequency appear to be adequate proxies of patient
experience. The results bolster the view that mirabegron may
be a good treatment option for OABpatients as improvements
in HRQoL measures are likely to be reflected in high patient
satisfaction. Nonetheless, studies that specifically evaluate
patient satisfaction are necessary to confirm this suggestion. In
addition, studies examining patient adherence with mirabeg-
ron are required; patient adherence with antimuscarinics, the
current mainstay of treatment for OAB, is poor, largely due to
intolerable side effects, and itwill be interesting to seewhether
mirabegon’s favorable effects onQoLmeasures translate into
good adherence levels.
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